NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Phase 1 Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18
Max Age: N/A

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


PI3 Kinase Inhibitor;
Targeted Therapy;
Combination Therapy;
Precision Medicine

Recruitment Keyword(s)



PTEN-Mutant Solid Tumors;
PIK3CB-Mutant Solid Tumors

Investigational Drug(s)


Investigational Device(s)



Drug: AZD8186
Drug: docetaxel

Supporting Site

National Cancer Institute


Some solid tumors have a defect in a gene called PTEN or PIK3CB. These defects can occur in many cancer types, such as prostate, breast, and lung. Researchers want to test a combination of drugs to treat these cancers.


To test the safety of AZD8186 at different doses when given with docetaxel, and to find out what effects the combinations have on people.


Adults age 18 and older with advanced cancer that shows a defect in the PTEN or PIK3CB gene and for which standard therapies do not exist or are no longer effective.


Participants will be screened with a physical exam and medical history. They will have an electrocardiogram to measure the heart s electrical activity. They will give blood and urine samples. They may have a tumor biopsy.

Each week, participants will take AZD8186 tablets twice a day for 5 days in a row followed by 2 days off. They will get docetaxel in a vein over 60 minutes every 3 weeks.

Participants will take AZD8186 and docetaxel for as long as they benefit from drugs and are not having serious side effects. They will get a medicine diary to use at home.

Some participants may have a biopsy before starting AZD8186 and again after a few days of treatment.

Participants will have computed tomography (CT) scans or magnetic resonance imaging of the abdomen and pelvis. They will have CT scans of the chest.

Participants will have a follow-up phone call a month after treatment ends. They may also have a scan every 3 months.

--Back to Top--



-Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.

-Patients must be able to swallow and retain oral medications and be without gastrointestinal illnesses that would preclude absorption of AZD8186.

-Unlimited prior therapies allowed

-Docetaxel appropriate

--Patients who have not received prior docetaxel (or other taxane therapy) in the advanced setting are eligible for all cohorts

--Patients who have previously received docetaxel(or other taxane therapy) in the advanced setting are eligible for the dose escalation cohort only, if anticipated to have maintained taxane sensitivity and in the opinion of the investigator would still benefit from further docetaxel therapy.

- Age >=18 years.

--Because no dosing or adverse event data are currently available on the use of AZD8186 in combination with Docetaxel in patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.

- ECOG performance status <=2 (Karnofsky >=60%)

-Patients must have normal organ and marrow function as defined below:

--leukocytes >=3,000/mcL

--absolute neutrophil count >=1,500/mcL

--hemoglobin >=8 g/L

--platelets >=100,000/mcL

--total bilirubin* within normal institutional limits

--AST(SGOT)/ALT(SGPT) <=1.5 (SqrRoot) institutional upper limit of normal

--creatinine within normal institutional limits OR

--creatinine clearance >=60 mL/min/1.73 m squared for patients with creatinine levels above institutional normal.

-PTEN or PIK3CB mutated advanced solid tumor.

--PTEN loss of function mutation or PIK3CB gain of function mutation identified by local CLIA certified next generation sequencing (NGS).

--Breast cancers patients enrolled on this study must have either:

---Estrogen receptor positive and HER2 negative breast cancer

---Triple negative breast cancer

- Adequate archival tissue (metastatic tissue sample is preferable but primary tumor tissue will be acceptable) or willing to undergo pre-treatment biopsy (for central confirmation of molecular alteration and PTEN immunohistochemical assessment) if adequate archival tissue is unavailable.

- The effects of AZD8186 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of AZD8186 administration.

-Ability to understand and the willingness to sign a written informed consent document.

-Cohort specific eligibility:

--Dose escalation cohort:

---Prior receipt of docetaxel is permitted

---Measurable disease is not required for enrollment

--Pharmacodynamic expansion cohort:

---Prior receipt of docetaxel is not permitted

---Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >=20 mm (>=2 cm) by chest x-ray or as >=10 mm (>=1 cm) with CT scan, MRI, or calipers by clinical exam.

---Consent to allow mandatory paired (pre- and on- treatment) fresh tissue biopsies if deemed safe to do so for quantitation of Akt pathway signaling proteins

--Disease specific expansion cohorts

---Prior receipt of docetaxel is not permitted

---Patients (excepting the prostate cancer patients) must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for nonnodal lesions and short axis for nodal lesions) as >=20 mm (>=2 cm) by chest x-ray or as >=10 mm (>=1 cm) with CT scan, MRI, or calipers by clinical exam

---Breast cancers patients enrolled on this study must have:

----Metastatic or advanced (incurable and unresectable) HER2 negative breast cancer regardless of estrogen receptor status (both hormone receptor positive and triple negative patients are eligible)

----Received hormonal therapy, as appropriate based on their hormone receptor status. Hormone receptor positive patients who have not received endocrine therapy for recurrent/metastatic disease are eligible, permitted their physician feels they are not appropriate for first line endocrine therapy, for example for high risk visceral metastatic disease.

---Prostate cancers patients enrolled on this study (applies to all prostate cancer patients treated on parts 1, 2, and 3) must have:

----Metastatic or advanced (incurable and unresectable) castration resistant metastatic cancer

----Received at least one additional line of anti-androgen therapy with abiraterone or enzalutamide.

----Measurable disease is not required for enrollment


-HER2 positive breast cancer.

-Prior treatment with PI3K/AKT inhibitors.

-Any known concurrent RAF or PIK3CA mutation.

-Patients who have had chemotherapy, radiotherapy, immunotherapy or anticancer agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of the first dose of study treatment, except hormonal therapy with LHRH analogues for medical castration in patients with prostate cancer and breast cancer, which are permitted

-Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1)

-Patients who are receiving any other investigational agents.

-Patients with known, untreated or unstable brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with treated brain metastases are eligible if the metastases have been radiographically and clinically stable for at least one month. If on steroids for this indication, the patient must be on a stable dose for at least one month.

-History of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AZD8186 or Docetaxel or to Docetaxel itself.

-Patients receiving any medications or substances that are strong inhibitors and/or strong or moderate inducers of CYP3A4 are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequentlyupdated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-thecounter medicine or herbal product.

-Existing bleeding or condition associated with increased risk of bleeding

-Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

-Pregnant women are excluded from this study because AZD8186 is a PI3K inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AZD8186, breastfeeding should be discontinued if the mother is treated with AZD8186. These potential risks may also apply to other agents used in this study.

-HIV-Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:

--A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong inhibitors and strong or moderate inducers of CYP3A4

--No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

--A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test

--Back to Top--


Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets. 2014 Jan;15(1):65-79. doi: 10.2174/1389450114666140106100909. PMID: 24387334; PMCID: PMC4310752.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST. Inhibition of PI3K <= signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. Mol Cancer Ther. 2015 Jan;14(1):48-58. doi: 10.1158/1535-7163.MCT-14-0406. Epub 2014 Nov 14. PMID: 25398829.

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Naoko Takebe, M.D.
National Cancer Institute (NCI)
(240) 541-4515

Jennifer H. Zlott
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 8D53
10 Center Drive
Bethesda, Maryland 20892
(240) 760-6046

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--